Plasma physostigmine concentrations after oral administration. 1985

N S Sharpless, and L J Thal

UI MeSH Term Description Entries
D008297 Male Males
D010830 Physostigmine A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. Eserine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

N S Sharpless, and L J Thal
March 1985, Lancet (London, England),
N S Sharpless, and L J Thal
November 1950, American journal of clinical pathology,
N S Sharpless, and L J Thal
October 1999, Journal of analytical toxicology,
N S Sharpless, and L J Thal
January 1980, Acta dermato-venereologica,
N S Sharpless, and L J Thal
May 1981, British journal of anaesthesia,
N S Sharpless, and L J Thal
June 1976, Minerva pediatrica,
N S Sharpless, and L J Thal
June 1979, British journal of anaesthesia,
N S Sharpless, and L J Thal
January 1986, Pediatric hematology and oncology,
N S Sharpless, and L J Thal
February 1996, The Tokai journal of experimental and clinical medicine,
N S Sharpless, and L J Thal
April 2020, Obstetrics and gynecology,
Copied contents to your clipboard!